Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harold E Glass

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Contemporary Clinical Trials|October 7, 2008
The profile of the one-time 1572 investigatorHarold E Glass
Disease Management : DM|March 24, 2004
Do clinical grant payment practices in phase 3 clinical trials influence subsequent clinical investigator prescribing behavior?Harold E Glass
Therapeutic Innovation & Regulatory Science|February 20, 2020
Open Payments and the US Clinical LandscapeHarold E Glass
Contemporary Clinical Trials|May 28, 2009
Managing clinical grant costsHarold E Glass, Karen Hollander
Therapeutic Innovation & Regulatory Science|September 18, 2018
ClinicalTrials.gov: An Underutilized Source of Research Data About the Design and Conduct of Commercial Clinical TrialsHarold E Glass, Lucas M Glass, Jeffrey J DiFrancesco
Therapeutic Innovation & Regulatory Science|September 21, 2018
Pharmaceutical Organizational Size and Phase 3 Clinical Trial Completion TimesHarold E Glass, Lucas M Glass, Phuong Tran, et al.
Therapeutic Innovation & Regulatory Science|September 18, 2018
Are Phase 3 Clinical Trials Really Becoming More Complex?Harold E Glass, Jeffrey J DiFrancesco, Lucas M Glass, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Contemporary Clinical Trials|October 7, 2008
The profile of the one-time 1572 investigatorHarold E Glass
Disease Management : DM|March 24, 2004
Do clinical grant payment practices in phase 3 clinical trials influence subsequent clinical investigator prescribing behavior?Harold E Glass
Therapeutic Innovation & Regulatory Science|February 20, 2020
Open Payments and the US Clinical LandscapeHarold E Glass
Contemporary Clinical Trials|May 28, 2009
Managing clinical grant costsHarold E Glass, Karen Hollander
Therapeutic Innovation & Regulatory Science|September 18, 2018
ClinicalTrials.gov: An Underutilized Source of Research Data About the Design and Conduct of Commercial Clinical TrialsHarold E Glass, Lucas M Glass, Jeffrey J DiFrancesco
Therapeutic Innovation & Regulatory Science|September 21, 2018
Pharmaceutical Organizational Size and Phase 3 Clinical Trial Completion TimesHarold E Glass, Lucas M Glass, Phuong Tran, et al.
Therapeutic Innovation & Regulatory Science|September 18, 2018
Are Phase 3 Clinical Trials Really Becoming More Complex?Harold E Glass, Jeffrey J DiFrancesco, Lucas M Glass, et al.
Pageof 1